Back to Ingredient Dictionary

Common Name(s): P-butylresorcinol,rucinol

CAS Number: 18979-61-8

DESCRIPTION

What It Does: Provides exceptional brightening through the most potent tyrosinase inhibition of any commonly used cosmetic brightening agent.

Why It's Used: The most potent tyrosinase inhibitor available in cosmetics โ€“ exceptional for refractory hyperpigmentation and melasma where standard brighteners provide insufficient efficacy.

How It Works: Resorcinol backbone competitively inhibits both tyrosine hydroxylase (reaction 1) and dopa oxidase (reaction 2) activities of tyrosinase. n-butyl chain provides superior membrane affinity for enhanced delivery to melanosomes.

Typically Found In: High-potency brightening serums,melasma treatments,stubborn hyperpigmentation products

TECHNICAL DETAILS

Primary Category: Active ingredient โ€“ resorcinol tyrosinase inhibitor

Secondary Functions: Dual tyrosinase reaction inhibition,potent brightening

Application Areas:

Facial Skincare

Body Care

Hair Care

Beard Care

Color Cosmetics (Makeup)

Dietary/Oral Supplements

Typical Concentration Range: 0.1%โ€“1%

SOURCING & ETHICS

Vegan Status: Yes โ€“ synthetic

Halal Status: Yes

Source Notes: Synthetic or plant-derived.

SKIN COMPATIBILITY

Irritancy Rating: 2/5 โ€“ low to moderate

Comedogenicity Rating: 0/5 โ€“ non-comedogenic

Sensitivity Concerns: Use with spf; introduce gradually. photosensitizing.

Safe for Sensitive Skin: Yes

SAFETY & COMPATIBILITY

Safety Profile: Excellent safety profile. use with spf for maximum efficacy. ewg score: 1.

Works Well With: Niacinamide,vitamin c,alpha-arbutin,tranexamic acid,spf

Avoid Combining With: No significant incompatibilities

SCIENTIFIC NOTE

4-butylresorcinol's inhibition of both tyrosinase catalytic reactions (tyrosineโ†’dopa and dopaโ†’dopaquinoneoxidase) is unique among common brighteners. most tyrosinase inhibitors only block the first reaction (tyrosineโ†’dopa). blocking both steps provides more complete melanin biosynthesis inhibition.

Last Verified: Cosing database,choi et al. 4-butylresorcinol study,sccs opinion on butylresorcinol

Primary Sources: 2026-03-12